that has to work across the board. it is not going to necessarily solve the direct problems. yeah it is not a stiletto. it s a sledgehammer. and part of the problem here is that they use a lot of data. economists like you and the fed, they study, study, study data. but it s as much art as science. what is the danger here? what are people worried about? the fed has been pretty clear this week yet another fed official said, okay, we will get this. we will tackle inflation. and the truth is, betsey, they can t. cam. inflation can be solved. the problem is that the fed can try and solve it so hard that we end up in a recession. right. so, the whole thing that the fed is trying to do is make sure that demand is not greater than supply. so, they can bring demand down. the problem is that if they bring demand down a lot, and then we end up in a recession they want to bring it down just enough. that s why you hear people talking about the goldilocks economy. you bring down demand, ge
are what you describe supply. we don t have quite enough to meet demand. so, with the fed is going to try to do is tamp down our demand by raising interest rates. and that is kind of a thing that has to work across the board. it is not going to necessarily solve the direct problems. yeah it is not a stiletto. it s a sledgehammer. and part of the problem here is that they use a lot of data. economists like you and the fed, they study, study, study data. but it s as much art as science. what is the danger here? what are people worried about? the fed has been pretty clear this week yet another fed official said, okay, we will get this. we will tackle inflation. and the truth is, betsey, they can t. inflation can be solved. the problem is that the fed can try and solve it so hard that we end up in a recession. right. so, the whole thing that the fed is trying to do is make sure that demand is not greater than supply. so, they can bring demand down. the problem is that if they bri
Sponsors of clinical trials in the United States have a regulatory responsibility under 21 CFR Part 312.50 to monitor the progress of clinical studies. Historically, Sponsors performed.
/PRNewswire/ Anavasi Diagnostics announced today that it has submitted the required EUA Clinical Study Data for the AscencioDx®, the molecular diagnostic.
/PRNewswire/ Anavasi Diagnostics announced today that it has submitted the required EUA Clinical Study Data for the AscencioDx®, the molecular diagnostic.